Ginkgo Bioworks Holdings, Inc. Financials

Market Capitalization $None as of Jan. 11, 2021

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE	-3.54
Price to Sales TTM	$8.37
Price to Book MRQ	$1.74
Enterprise to Revenue	4.81
Enterprise to EBITDA	-1.83

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	78.52%
Operating Margin	-515.53%
Return on Assets TTM	-21.82%
Return on Equity TTM	-63.02%

Income Statement

Revenue TTM	$251,455,008
Revenue per Share TTM	$0.13
Quarterly Revenue Growth	-64.60%
Gross Profit TTM	$197,450,000
EBITDA	$-662,280,000
Net Income to Common TTM	$-892,868,992
Diluted EPS TTM	$-0.46
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$944,073,024
Total Cash per Share MRQ	$0.47
Total Debt MRQ	$
Total Debt to Equity MRQ	22.08
Current Ratio MRQ	6.11
Book Value per Share MRQ	$0.55

Cash Flow

Operating Cash Flow TTM	$-295,500,000
Levered Free Cash Flow TTM	$-116,135,376

DNA Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	1,700,269,952
Float Shares	1,173,370,985
Avg 10 Volume	62,919,690
Avg 30 Volume	None
Shares Short	266,527,056
Short Ratio	12.74
Short % of Shares	21.78%
% Held by Insiders	6.54%
% Held by Institutions	80.43%

Stock Price Summary

Beta	1.36
Fifty Two Week Low	$0.74
Fifty Two Week High	$2.55
Fifty Two Week Change	-43.46%
Day 50 MA	$1.10
Day 200 MA	$1.51

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date